JP5500397B2 - 機械的安定性が改善した埋め込み型医療デバイスコーティング - Google Patents
機械的安定性が改善した埋め込み型医療デバイスコーティング Download PDFInfo
- Publication number
- JP5500397B2 JP5500397B2 JP2011500894A JP2011500894A JP5500397B2 JP 5500397 B2 JP5500397 B2 JP 5500397B2 JP 2011500894 A JP2011500894 A JP 2011500894A JP 2011500894 A JP2011500894 A JP 2011500894A JP 5500397 B2 JP5500397 B2 JP 5500397B2
- Authority
- JP
- Japan
- Prior art keywords
- layer
- coating
- device body
- poly
- implantable medical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000576 coating method Methods 0.000 title claims description 51
- 239000011248 coating agent Substances 0.000 title claims description 47
- 239000012867 bioactive agent Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 229920000118 poly(D-lactic acid) Polymers 0.000 claims description 16
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000010410 layer Substances 0.000 description 63
- 229920000642 polymer Polymers 0.000 description 48
- 239000003814 drug Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 239000000463 material Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000035882 stress Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 229940065514 poly(lactide) Drugs 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- LPEKGGXMPWTOCB-UHFFFAOYSA-N 8beta-(2,3-epoxy-2-methylbutyryloxy)-14-acetoxytithifolin Natural products COC(=O)C(C)O LPEKGGXMPWTOCB-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 229910000684 Cobalt-chrome Inorganic materials 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 229910001257 Nb alloy Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 229910001362 Ta alloys Inorganic materials 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 208000004608 Ureteral Obstruction Diseases 0.000 description 1
- 206010070693 Vascular dissection Diseases 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 229910001093 Zr alloy Inorganic materials 0.000 description 1
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical compound [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000012659 cardioprotective agent Substances 0.000 description 1
- 229940045200 cardioprotective agent Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- NWSBNVVOFKKFNV-UHFFFAOYSA-N chloroform;oxolane Chemical compound ClC(Cl)Cl.C1CCOC1 NWSBNVVOFKKFNV-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000010952 cobalt-chrome Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229940057867 methyl lactate Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 239000010955 niobium Substances 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000052 poly(p-xylylene) Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000015670 renal artery disease Diseases 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229920000576 tactic polymer Polymers 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/08—Coatings comprising two or more layers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
Description
本発明は、機械的安定性が改善した埋め込み型医療デバイスコーティング、及びそのようなコーティングでコーティングされた医療デバイスに関する。
ポリマーは、引っ張り強度、降伏応力、硬度、剛性、伸張性、及びガス透過性等のバルク特性により一般的に特徴づけられる。製造業者は、ある特定のポリマーが特定の用途で有用かどうか判断するためにこれらの特性を利用する。例えば、モータサイクル用のヘルメット等で用いるために硬く、耐衝撃性のある材料が求められる場合、上記バルク特性を示すポリマーが選択される。拡張型冠動脈ステントで用いるような場合など、使用目的上、柔軟性、靭性、及び伸張性が必要な場合には、異なる種類のポリマーが選択される。
本発明は、デバイス本体と、前記デバイス本体上に配置されたポリ(D−乳酸)(PDLA)及びポリ(L−乳酸)(PLLA)のステレオコンプレックスを含むコーティングと、を備える、埋め込み型医療デバイスに関し、前記コーティングは、プライマー層、リザーバー層、トップコート層、又はこれらの任意の組み合わせを形成しうる。このデバイス本体は、ステントでありうる。
本発明は、デバイス本体と、ポリ(D−乳酸)及びポリ(L−乳酸)のステレオコンプレックスを含む、前記デバイス本体上に配置されたコーティングと、を備える、埋め込み型医療デバイスに関し、前記コーティングは、プライマー層、リザーバー層、トップコート層、又はこれらの任意の組み合わせを形成しうる。このデバイス本体は、ステントでありうる。
Claims (13)
- デバイス本体と、
前記デバイス本体上に配置されたコーティングと、を備え、
前記コーティングが、前記デバイス本体上に直接設けられたプライマー層を含み、
前記プライマー層のみが、ポリ(D−乳酸)及びポリ(L−乳酸)のステレオコンプレックスを含み、
前記コーティングが、リザーバー層及びトップコート層の少なくとも1つをさらに含む、埋め込み型医療デバイス。 - 前記コーティングが、前記リザーバー層を含む、請求項1に記載の埋め込み型医療デバイス。
- 前記コーティングが、前記リザーバー層上に配置されたトップコート層をさらに含む、請求項2に記載の埋め込み型医療デバイス。
- デバイス本体と、
前記デバイス本体上に配置されたコーティングと、を備え、
前記コーティングが、前記デバイス本体上に直接設けられたプライマー層と、リザーバー層と、前記リザーバー層上に配置されたトップコート層とを含み、
前記プライマー層及び前記リザーバー層のみが、ポリ(D−乳酸)及びポリ(L−乳酸)のステレオコンプレックスを含む、埋め込み型医療デバイス。 - 前記リザーバー層が、1種又は複数種の生物活性剤を含む、請求項2〜4のいずれか一項に記載の埋め込み型医療デバイス。
- 前記デバイス本体がステントである、請求項1〜5のいずれか一項に記載の埋め込み型医療デバイス。
- デバイス本体を用意するステップと、
前記デバイス本体上にコーティングを配置するステップと、を含み、
前記コーティングが、前記デバイス本体上に直接設けられたプライマー層を含み、
前記プライマー層のみが、ポリ(D−乳酸)及びポリ(L−乳酸)のステレオコンプレックスを含み、
前記コーティングが、リザーバー層及びトップコート層の少なくとも1つをさらに含む、
埋め込み型医療デバイスコーティングの安定性を増大させる方法。 - 前記コーティングが、前記リザーバー層を含む、請求項7に記載の方法。
- 前記コーティングが、前記リザーバー層上に配置されたトップコート層を含む、請求項8に記載の方法。
- デバイス本体を用意するステップと、
前記デバイス本体上にコーティングを配置するステップと、を含み、
前記コーティングが、前記デバイス本体上に直接設けられたプライマー層と、リザーバー層と、前記リザーバー層上に配置されたトップコート層とを含み、
前記プライマー層及び前記リザーバー層のみが、ポリ(D−乳酸)及びポリ(L−乳酸)のステレオコンプレックスを含む、埋め込み型医療デバイスコーティングの安定性を増大させる方法。 - 前記リザーバー層が、1種又は複数種の生物活性剤を含む、請求項8〜10のいずれか一項に記載の方法。
- 1種又は複数種の前記生物活性剤が、イオン結合、水素結合又は共有結合によって、前記リザーバー層中のポリ(D−乳酸)及びポリ(L−乳酸)のステレオコンプレックスに連結されている、請求項11に記載の方法。
- 前記デバイス本体が、ステントである、請求項7〜12のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/052,452 US8377116B2 (en) | 2008-03-20 | 2008-03-20 | Implantable medical device coatings with improved mechanical stability |
US12/052,452 | 2008-03-20 | ||
PCT/US2009/037375 WO2009117398A2 (en) | 2008-03-20 | 2009-03-17 | Implantable medical device coatings with improved mechanical stability |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011517969A JP2011517969A (ja) | 2011-06-23 |
JP2011517969A5 JP2011517969A5 (ja) | 2014-01-16 |
JP5500397B2 true JP5500397B2 (ja) | 2014-05-21 |
Family
ID=40637707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011500894A Active JP5500397B2 (ja) | 2008-03-20 | 2009-03-17 | 機械的安定性が改善した埋め込み型医療デバイスコーティング |
Country Status (4)
Country | Link |
---|---|
US (1) | US8377116B2 (ja) |
EP (1) | EP2268329B1 (ja) |
JP (1) | JP5500397B2 (ja) |
WO (1) | WO2009117398A2 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010037141A1 (en) | 2008-09-29 | 2010-04-01 | Cardiaq Valve Technologies, Inc. | Heart valve |
WO2010040009A1 (en) | 2008-10-01 | 2010-04-08 | Cardiaq Valve Technologies, Inc. | Delivery system for vascular implant |
EP2419050B2 (en) | 2009-04-15 | 2023-10-18 | Edwards Lifesciences CardiAQ LLC | Vascular implant and delivery system |
US8579964B2 (en) | 2010-05-05 | 2013-11-12 | Neovasc Inc. | Transcatheter mitral valve prosthesis |
US9308087B2 (en) | 2011-04-28 | 2016-04-12 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US9554897B2 (en) | 2011-04-28 | 2017-01-31 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
KR101360106B1 (ko) * | 2012-04-18 | 2014-02-12 | 한국과학기술연구원 | 표면 개질된 세라믹 입자 및 스테레오 콤플렉스를 이루는 생분해성 고분자를 포함하는 생체 이식물, 이의 염증 억제 및 기계적 물성 향상용으로서의 용도 및 그 제조 방법 |
US9345573B2 (en) | 2012-05-30 | 2016-05-24 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US10583002B2 (en) | 2013-03-11 | 2020-03-10 | Neovasc Tiara Inc. | Prosthetic valve with anti-pivoting mechanism |
US9681951B2 (en) | 2013-03-14 | 2017-06-20 | Edwards Lifesciences Cardiaq Llc | Prosthesis with outer skirt and anchors |
US9572665B2 (en) | 2013-04-04 | 2017-02-21 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
CN108338989B (zh) * | 2017-08-08 | 2021-12-17 | 新昕医药科技(上海)有限公司 | 冠脉药物洗脱支架的复合抗再狭窄药物及其控释系统 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04226125A (ja) | 1990-06-23 | 1992-08-14 | Boehringer Ingelheim Kg | ポリ−d,l−ラクチドの製造方法及び活性物質の担体としてのそれらの使用 |
US5346966A (en) | 1991-12-31 | 1994-09-13 | E. I. Du Pont De Nemours And Company | L,d-polylactide copolymers with controlled morphology |
US5338822A (en) | 1992-10-02 | 1994-08-16 | Cargill, Incorporated | Melt-stable lactide polymer composition and process for manufacture thereof |
PT2298366E (pt) | 2000-03-13 | 2012-11-20 | Kyoto Iryo Sekkei Kk | Material linear para endoprótese intravascular e endoprótese intravascular que utiliza o mesmo |
US6939376B2 (en) | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
EP1559440B1 (en) | 2002-10-29 | 2015-09-23 | Toray Industries, Inc. | Vascular embolization meterial |
US20050112170A1 (en) * | 2003-11-20 | 2005-05-26 | Hossainy Syed F. | Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same |
US8110211B2 (en) * | 2004-09-22 | 2012-02-07 | Advanced Cardiovascular Systems, Inc. | Medicated coatings for implantable medical devices including polyacrylates |
US8778375B2 (en) * | 2005-04-29 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Amorphous poly(D,L-lactide) coating |
US20070043434A1 (en) | 2005-08-18 | 2007-02-22 | David Meerkin | Biodegradable endovascular stent using stereocomplexation of polymers |
JP5102200B2 (ja) * | 2006-03-30 | 2012-12-19 | テルモ株式会社 | 生体内留置物 |
WO2007116646A1 (ja) | 2006-04-04 | 2007-10-18 | Terumo Kabushiki Kaisha | 生体内留置物 |
US7862830B2 (en) * | 2006-07-13 | 2011-01-04 | Abbott Cardiovascular Systems Inc. | Stereocomplex-forming composition and implantable medical device comprising same |
US20080020014A1 (en) * | 2006-07-19 | 2008-01-24 | Paul Consigny | Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders |
-
2008
- 2008-03-20 US US12/052,452 patent/US8377116B2/en not_active Expired - Fee Related
-
2009
- 2009-03-17 EP EP09722969.4A patent/EP2268329B1/en not_active Not-in-force
- 2009-03-17 JP JP2011500894A patent/JP5500397B2/ja active Active
- 2009-03-17 WO PCT/US2009/037375 patent/WO2009117398A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US8377116B2 (en) | 2013-02-19 |
US20090240325A1 (en) | 2009-09-24 |
EP2268329A2 (en) | 2011-01-05 |
EP2268329B1 (en) | 2013-11-06 |
WO2009117398A2 (en) | 2009-09-24 |
WO2009117398A3 (en) | 2010-06-03 |
JP2011517969A (ja) | 2011-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5500397B2 (ja) | 機械的安定性が改善した埋め込み型医療デバイスコーティング | |
JP5932073B2 (ja) | ステントの分解を調節し、pHを中性に維持するためのコーティングを有する吸収性ステント | |
US9254350B2 (en) | Implantable medical devices having bioabsorbable primer polymer coatings | |
Mani et al. | Coronary stents: a materials perspective | |
JP5594534B2 (ja) | 調節可能な疎水性を備えた生体吸収性コーティング | |
ES2451653T3 (es) | Dispositivo médico implantable con revestimiento de suministro de fármacos de poliéster de erosión superficial | |
JP5522635B2 (ja) | 血液適合性、及び/又は治癒促進性を有する上塗りを備えた、薬物溶出性の埋込型医療デバイス | |
US20100023116A1 (en) | Biocorrodible implant with a coating containing a drug eluting polymer matrix | |
US20080124372A1 (en) | Morphology profiles for control of agent release rates from polymer matrices | |
US20090240323A1 (en) | Controlled Degradation of Magnesium Stents | |
US20100119581A1 (en) | Medical Products That Release Pharmaceutically Active Substances | |
US9737395B2 (en) | Systems and methods for reducing scarring | |
JP5695107B2 (ja) | ホスホリルコリン基を含有する共重合体とその製造及び利用方法 | |
WO2004000382A1 (en) | Silicone blends and composites for drug delivery | |
Patel et al. | Current status and future prospects of drug eluting stents for restenosis/Sadašnjost i budućnost stentova za restenozu koji otpuštaju lijekove | |
JP5542052B2 (ja) | 薄い吸収性コーティングを有する埋め込み型医療器具 | |
Ebrahimi-Nozari et al. | Multimodal effects of asymmetric coating of coronary stents by electrospinning and electrophoretic deposition | |
US20120150282A1 (en) | Implant having a paclitaxel-releasing coating | |
CN105025946B (zh) | 包含大环三烯内酯药物和最少抗氧化稳定剂的可植入医疗装置及制造方法 | |
JP2002172159A (ja) | 体内埋め込み医療器具 | |
US20100015201A1 (en) | Implant with coating | |
WO2009114326A2 (en) | Implantable medical device comprising a pro-healing poly (ester-amide) | |
Hayenga et al. | Perspectives on the Mechanics of Biomaterials in Medical Devices | |
US20090228097A1 (en) | A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device | |
PATEL et al. | Sadašnjost i budućnost stentova za restenozu koji otpuštaju lijekove |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120131 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130820 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20131120 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140212 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140226 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5500397 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |